First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

A South African Hero: You

There’s a 99.7% chance that this isn’t for you. Only 0.3% of our readers have responded to this call for action.

Those 0.3% of our readers are our hidden heroes, who are fuelling our work and impacting the lives of every South African in doing so. They’re the people who contribute to keep Daily Maverick free for all, including you.

We need so many more of our readers to join them. The equation is quite simple: the more members we have, the more reporting and investigations we can do, and the greater the impact on the country. We are inundated with tip-offs; we know where to look and what to do with the information when we have it – we just need the means to help us keep doing this work.

Be part of that 0.3%. Be a Maverick. Be a Maverick Insider.

Support Daily Maverick→
Payment options

Brazil approves human trials for third COVID-19 vaccine

Newsdeck

COVID-19

Brazil approves human trials for third COVID-19 vaccine

epa08303752 Brazilian scientists in the Immunology laboratory of the Heart Institute (Incor) of the Faculty of Medicine of the University of Sao Paulo, in Sao Paulo, Brazil, 17 March 2020 (issued 18 March 2020). Brazilian scientists develop a coronavirus vaccine with a different method than those used so far by the pharmaceutical industry and groups of researchers from other countries, who expect it to be tested on animals in the coming months. It is the current great challenge of the international scientific community and Brazil, as a power in Latin America, has joined this agonizing race to discover an effective immune response against the virus that has paralyzed half the world, although it has done so with a different approach. Meanwhile, Brazilians remain skeptical about the extent of this global pandemic in the country, where there are about 300 confirmed cases and at least one death from COVID-19. EPA-EFE/Sebastiao Moreira
By Reuters
22 Jul 2020 0

BRASILIA/SAO PAULO, July 21 (Reuters) - Brazil on Tuesday approved clinical trials starting in August for a potential COVID-19 vaccine under joint development by U.S. pharmaceutical company Pfizer and Germany's BioNTech - the third such vaccine to be tested in the country.

With more than 2.1 million confirmed cases of the novel coronavirus, Brazil has the world’s worst outbreak outside the United States, making it prime testing grounds for vaccines.

“We are proud to have Brazilian volunteers participating in this global effort, which could play a critical role in the fight against COVID-19,” said Edson Moreira, who will lead the Pfizer/BioNTech trial, according to a company statement.

Brazilian health regulator Anvisa had previously approved trials for possible vaccines developed in the U.K. and China.

On Tuesday, the first Brazilian volunteer was injected with a possible coronavirus vaccine developed by China’s Sinovac Biotech in Sao Paulo.

A vaccine developed by the University of Oxford and AstraZeneca entered clinical trials in Brazil in June.

The country is also scrambling to secure supplies of potential vaccines, in case they are proven successful.

Interim Health Minister Eduardo Pazuello said on Tuesday that negotiations are underway with U.S. biotech firm Moderna Inc for Brazil to get priority in purchasing a potential COVID-19 vaccine the company is developing.

Pazuello said Brazil already has an understanding with AstraZeneca for the firm to deliver 30 million doses of its potential vaccine.

Sinovac has agreed to deliver enough vaccine to immunize 60 million Brazilians, if its vaccine is proven effective.

Brazil is also developing possible vaccines domestically, which are still in pre-clinical testing stages. (Reporting by Ricardo Brito in Brasilia and Pedro Fonseca and Eduardo Simoes in Sao Paulo; writing by Jake Spring; Editing by Brad Haynes and Alistair Bell)

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted